Related Experiment Video

Updated: Jan 19, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.8K

Kinase Inhibitors and Ovarian Cancer

Periklis Katopodis1,2, Dimple Chudasama3, Gurleen Wander4

  • 1Biosciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK. periklis.katopodis@brunel.ac.uk.

Cancers
|September 25, 2019
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) combined with chemotherapy show promise for improving progression-free survival in ovarian cancer. Mechanistic target of rapamycin (mTOR) inhibitors appear less effective, necessitating further research into novel therapeutic strategies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ovarian cancer is a leading cause of cancer death in women and the most fatal gynecological malignancy.
  • Current treatments involving surgery and chemotherapy offer limited long-term survival benefits, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

  • To review the clinical applications of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer.
  • To evaluate the efficacy and potential of these targeted therapies in improving patient outcomes.

Main Methods:

  • Review of emerging data from Phase I and II clinical trials.
  • Analysis of the role of TKIs and mTOR inhibitors in combination with chemotherapy.

Main Results:

  • Combinatorial therapy with TKIs and chemotherapy demonstrates potential for enhancing progression-free survival (PFS) in ovarian cancer patients.
  • Adverse effects were noted with combination therapies.
  • mTOR inhibitors showed limited efficacy in current clinical investigations.

Conclusions:

  • Targeted therapies, particularly TKIs in combination with chemotherapy, represent a promising avenue for improving ovarian cancer treatment.
  • Further research is warranted to explore multi-targeted pathway inhibition and advance promising agents to Phase III trials.
Keywords:
TKIkinase inhibitorsmTORovarian cancerrapalogs

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
598